Edwards Lifesciences Corp. Price Target Raised to $82.00 at Stifel Nicolaus (EW)
Research analysts at Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences Corp. (NYSE:EW) from $81.00 to $82.00 in a report released on Thursday, American Banking News reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 14.16% from the company’s current price.
Edwards Lifesciences Corp. (NYSE:EW) traded down 0.57% on Thursday, hitting $71.42. 43,211 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 1-year low of $62.34 and a 1-year high of $110.79. The stock has a 50-day moving average of $70.96 and a 200-day moving average of $71.31. The company has a market cap of $8.018 billion and a price-to-earnings ratio of 21.00.
Edwards Lifesciences Corp. (NYSE:EW) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter in the prior year, the company posted $0.57 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis. Analysts expect that Edwards Lifesciences Corp. will post $3.07 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Edwards Lifesciences Corp. (NYSE:EW) in a research note to investors on Tuesday, September 10th. They now have a $90.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Edwards Lifesciences Corp. (NYSE:EW) from $72.00 to $75.00 in a research note to investors on Tuesday, September 10th. They now have a “sector perform” rating on the stock. Finally, analysts at Zacks upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $74.00 price target on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $80.75.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.